Advance of A Board Range of Indications

Humanized GPC3-CAR-T Cell ( HCC )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Humanized GPC3-CAR-T Cell ( SLC )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Humanized EGFR-CAR-T Cell ( GBM )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Humanized CD19-T CAR-T Cell ( ALL/NHL )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Humanized CLD18.2-CAR-T Cell ( Gastric / Pancreatic Cancer )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Human MSLN-CAR T Cell ( Pancreatic Cancer )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Human BCMA-CAR-T Cell ( Multiple Myeloma )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Human IL13Rα2-CAR-T Cell ( Glioma )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Human CD22-CAR-T Cell ( All/NHL )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

Human WT1-CAR-T Cell ( AML )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ

CAR-01-T Cell ( Variou solid tumors )

Pre-Clinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ